| 1.26 -0.04 (-3.08%) | 12-08 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 2.47 |
1-year : | 3.1 |
| Resists | First : | 2.12 |
Second : | 2.65 |
| Pivot price | 1.77 |
|||
| Supports | First : | 1.25 |
Second : | 1.04 |
| MAs | MA(5) : | 1.37 |
MA(20) : | 1.91 |
| MA(100) : | 1.44  |
MA(250) : | 1.12 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 1.8 |
D(3) : | 3.4 |
| RSI | RSI(14): 32.6 |
|||
| 52-week | High : | 2.65 | Low : | 0.33 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ TOI ] has closed above bottom band by 12.7%. Bollinger Bands are 122% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 26 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.3 - 1.32 | 1.32 - 1.32 |
| Low: | 1.23 - 1.25 | 1.25 - 1.26 |
| Close: | 1.24 - 1.27 | 1.27 - 1.28 |
The Oncology Institute, Inc., an oncology company, provides medical oncology services in the United States. Its services include physician services, in-house infusion and dispensary, clinical trial services, radiation, outpatient stem cell transplants and transfusions programs, and patient support. The company also offers and manages clinical trial services, such as managing clinical trials, palliative care programs, and stem cell transplants services. It serves adult and senior cancer patients. The company operates 67 clinic locations. The Oncology Institute, Inc. was founded in 2007 and is based in Cerritos, California.
Mon, 04 Dec 2023
The Oncology Institute Expands its Specialty Medication Business by Opening Pharmacy Operations in California - Yahoo Finance
Wed, 29 Nov 2023
Is Oncology Institute Inc (TOI) a Winner in the Medical Care Facilities Industry? - InvestorsObserver
Fri, 17 Nov 2023
Is Oncology Institute Inc (TOI) Stock at the Top of the Medical Care Facilities Industry? - InvestorsObserver
Thu, 16 Nov 2023
Insider Sell Alert: Director Brad Hively Sells 47,000 Shares of The Oncology Institute Inc (TOI) - Yahoo Finance
Fri, 10 Nov 2023
The Oncology Institute, Inc. (NASDAQ:TOI) Stock Rockets 49% But Many Are Still Ignoring The Company - Simply Wall St
Wed, 08 Nov 2023
The Oncology Institute Reports Third Quarter 2023 Financial Results and Reaffirms Full Year 2023 Guidance - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical Care Facilities
|
|
| Shares Out | 74 (M) |
| Shares Float | 31 (M) |
| Held by Insiders | 19 (%) |
| Held by Institutions | 58.2 (%) |
| Shares Short | 447 (K) |
| Shares Short P.Month | 245 (K) |
| EPS | -0.89 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.98 |
| Profit Margin | -24.4 % |
| Operating Margin | -17 % |
| Return on Assets (ttm) | -14.4 % |
| Return on Equity (ttm) | -75.5 % |
| Qtrly Rev. Growth | 26.2 % |
| Gross Profit (p.s.) | 0.7 |
| Sales Per Share | 4.2 |
| EBITDA (p.s.) | -0.71 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -46 (M) |
| Levered Free Cash Flow | -30 (M) |
| PE Ratio | -1.42 |
| PEG Ratio | 0 |
| Price to Book value | 1.28 |
| Price to Sales | 0.29 |
| Price to Cash Flow | -2.01 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|